Photo of Marsha A. Moses,  PhD

Marsha A. Moses, PhD

Boston Children's Hospital

Boston Children's Hospital

Marsha A. Moses, PhD

Boston Children's Hospital

EDUCATIONAL TITLES

  • Julia Dyckman Andrus Professor of Surgery, Surgery, Harvard Medical School

Research Abstract

Marsha A. Moses is the Julia Dyckman Andrus Professor at Harvard Medical School and the Director of the Vascular Biology Program at Boston Children's Hospital. She has had a long-standing interest in identifying and characterizing the biochemical and molecular mechanisms that underlie the regulation of tumor growth and progression. Dr. Moses and her laboratory have discovered a number of angiogenesis inhibitors that function at both the transcriptional and translational level, some of which are being developed for clinical use.

Named a pioneer in the exciting field of Biomarker Medicine by the Journal of the National Cancer Institute, Dr. Moses established a Proteomics Initiative in her laboratory that has led to the discovery of panels of noninvasive urinary cancer biomarkers that can predict disease status and stage in cancer patients and that are sensitive and specific markers of disease progression and therapeutic efficacy of cancer drugs. A number of these urine tests have been made commercially available. These diagnostics and therapeutics are included in Dr. Moses’ significant patent portfolio which is composed of both US and foreign patents.

Dr. Moses’ basic and translational work has been published in such journals as Science, the New England Journal of Medicine, Cell and the Journal of Biological Chemistry, among others. Dr. Moses received a Ph.D. in Biochemistry from Boston University and completed a National Institutes of Health postdoctoral fellowship at Boston Children's Hospital and MIT. She is the recipient of a number of NIH and foundation grants and awards. Dr. Moses has been recognized with both of Harvard Medical School's mentoring awards, the A. Clifford Barger Mentoring Award (2003) and the Joseph B. Martin Dean’s Leadership Award for the Advancement of Women Faculty (2009). In 2013, she received the Honorary Member Award from the Association of Women Surgeons of the American College of Surgeons. Dr. Moses was elected to the Institute of Medicine of the National Academies of the United States in 2008 and to the National Academy of Inventors in 2013.

 

Publications

Powered by Harvard Catalyst
  • Jia D, Huang L, Bischoff J, Moses MA. The endogenous zinc finger transcription factor, ZNF24, modulates the angiogenic potential of human microvascular endothelial cells. FASEB J. 2015; 29:1371-82. PubMed
  • Shimura T, Dagher A, Sachdev M, Ebi M, Yamada T, Yamada T, Joh T, Moses MA. Urinary ADAM12 and MMP-9/NGAL Complex Detect the Presence of Gastric Cancer. Cancer Prev Res (Phila Pa) 2015; 8:240-8. PubMed
  • Pelton K, Coticchia CM, Curatolo AS, Schaffner CP, Zurakowski D, Solomon KR, Moses MA. Hypercholesterolemia Induces Angiogenesis and Accelerates Growth of Breast Tumors in Vivo. Am J Pathol 2014; 184:2099-110. PubMed
  • Foradori MJ, Chen Q, Fernandez CA, Harper J, Li X, Tsang PC, Langer R, Moses MA. Matrilin-1 is an inhibitor of neovascularization. J Biol Chem 2014. PubMed
  • Guo P, You JO, Yang J, Jia D, Moses MA, Auguste DT. Inhibiting Metastatic Breast Cancer Cell Migration via the Synergy of Targeted, pH-triggered siRNA Delivery and Chemokine Axis Blockade. Mol Pharm 2014. PubMed
  • Sreenivasan AK, Bachur CD, Lanier KE, Curatolo AS, Connors SM, Moses MA, Comi AM. Urine vascular biomarkers in Sturge-Weber syndrome. Vasc Med 2013; 18:122-8. PubMed
  • Jia D, Hasso SM, Chan J, Filingeri D, D'Amore PA, Rice L, Pampo C, Siemann DW, Zurakowski D, Rodig SJ, Moses MA. Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo. Blood 2013; 121:707-15. PubMed
  • Guo P, You JO, Yang J, Moses MA, Auguste DT. Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity. Biomaterials 2012; 33:8104-10. PubMed
  • Di Vizio D, Morello M, Dudley AC, Schow PW, Adam RM, Morley S, Mulholland D, Rotinen M, Hager MH, Insabato L, Moses MA, Demichelis F, Lisanti MP, Wu H, Klagsbrun M, Bhowmick NA, Rubin MA, D'Souza-Schorey C, Freeman MR. Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol 2012; 181:1573-84. PubMed
  • Yang J, McNeish B, Butterfield C, Moses MA. Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J. 2012. PubMed
  • Govindarajan B, Willoughby L, Band H, Curatolo AS, Veledar E, Chen S, Bonner MY, Abel MG, Moses MA, Arbiser JL. Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia. 2012; 4:11. PubMed
  • Mannelqvist M, Stefansson IM, Wik E, Kusonmano K, Raeder MB, Øyan AM, Kalland KH, Moses MA, Salvesen HB, Akslen LA. Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer 2012; 12:169. PubMed
  • Roy R, Moses MA. ADAM12 induces estrogen-independence in breast cancer cells. Breast Cancer Res Treat 2011. PubMed
  • Fernandez CA, Roy R, Lee S, Yang J, Panigrahy D, Van Vliet KJ, Moses MA. The anti-angiogenic peptide, Loop 6, binds IGF-IR. J Biol Chem 2010; 285:41886-95. PubMed
  • Becker CM, Louis G, Exarhopoulos A, Mechsner S, Ebert AD, Zurakowski D, Moses MA. Matrix metalloproteinases are elevated in the urine of patients with endometriosis. Fertil Steril 2010; 94:2343-6. PubMed
  • Dudley AC, Udagawa T, Melero-Martin JM, Shih SC, Curatolo A, Moses MA, Klagsbrun M. Bone marrow is a reservoir for pro-angiogenic myelomonocytic cells but not endothelial cells in spontaneous tumors. Blood 2010; 116:3367-71. PubMed
  • Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010; 28:2817-23. PubMed
  • Lee PS,Tsang SW,Moses MA,Trayes-Gibson Z,Hsiao LL,Jensen R,Squillace R,Kwiatkowski DJ. Rapamycin-insensitive Up-regulation of MMP2 and Other Genes in TSC2-deficient LAM-like Cells. Am J Respir Cell Mol Biol 2010; 42:227-34. PubMed
  • Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009; 27:5287-97. PubMed
  • Yang J, Moses MA. Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle 2009; 8:2347-52. PubMed
  • Chang SH,Kanasaki K,Gocheva V,Blum G,Harper J,Moses MA,Shih SC,Nagy JA,Joyce J,Bogyo M,Kalluri R,Dvorak HF. VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res 2009; 69:4537-44. PubMed
  • Manfredi MA,Fox VL,Zurakowski D,Kutok JL,Glickman JN,Moses MA. Matrix metalloproteinases in the urine and tissue of patients with juvenile polyps: potential biomarkers for the presence of polyps. J Pediatr Gastroenterol Nutr 2009; 48:405-11. PubMed
  • Yang J,Bielenberg DR,Rodig SJ,Doiron R,Clifton MC,Kung AL,Strong RK,Zurakowski D,Moses MA. Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci U S A 2009; 106:3913-8. PubMed
  • Roy R,Louis G,Loughlin KR,Wiederschain D,Kilroy SM,Lamb CC,Zurakowski D,Moses MA. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 2008; 14:6610-7. PubMed
  • Manfredi MA, Zurakowski D, Rufo PA, Walker TR, Fox VL, Moses MA. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2008; 14:1091-6. PubMed
  • Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 2008; 14:2378-86. PubMed
  • Alwayn IP, Verbesey JE, Kim S, Roy R, Arsenault DA, Greene AK, Novak K, Laforme A, Lee S, Moses MA, Puder M. A critical role for matrix metalloproteinases in liver regeneration. J Surg Res 2008; 145:192-8. PubMed
  • Klagsbrun M, Moses MA. Obituary: M. Judah Folkman (1933-2008). Nature 2008; 451:781. PubMed
  • Rickert D, Franke RP, Lendlein A, Kelch S, Moses MA. Influence of the surface structure of a multiblock copolymer on the cellular behavior of primary cell cultures of the upper aerodigestive tract in vitro. J Biomed Mater Res A 2007; 83:558-69. PubMed
  • Harper J, Yan L, Loureiro RM, Wu I, Fang J, D'Amore PA, Moses MA. Repression of vascular endothelial growth factor expression by the zinc finger transcription factor ZNF24. Cancer Res 2007; 67:8736-41. PubMed
  • Ge G, Fernandez CA, Moses MA, Greenspan DS. Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor. Proc Natl Acad Sci U S A 2007; 104:10010-5. PubMed
  • Smith ER, Manfredi M, Scott RM, Black PM, Moses MA. A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: case report. Neurosurgery 2007; 60:E1148-9; discussion E1149. PubMed
  • Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA. ADAM 12 cleaves ECM proteins: Correlation with cancer status and stage. J Biol Chem 2004; 279:51323-30. PubMed
  • Fern. Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor. J Biol Chem 2003; 278:40989-95. PubMed
  • Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001; 276:37258-65. PubMed
  • Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, Harper J, Tamvakopoulos G, Moses MA. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A 2000; 97:3884-9. PubMed
Hide